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Background
We are evaluating the immunogenicity and efficacy of a
nanoparticle vaccine (NPV) targeting the tumor marker
human aspartyl (asparaginyl) b-hydroxylase (HAAH).
HAAH is an embryonic protein that is over-expressed
on the surface of cancer cells, is demonstrated to be
responsible for cell proliferation, motility and invasive-
ness, processes which can be inhibited by anti-HAAH
antibodies in vitro. We have developed novel anticancer
NPVs in which portions of the HAAH molecule are
expressed on l-phage (200-300 copies per NPV). These
NPVs produce high-titer anti-HAAH polyclonal antibo-
dies in mice despite the fact that the HAAH protein is
highly conserved between mammalian species. We have
shown that the NPV inhibits tumor growth and metas-
tasis in mouse liver and breast cancer models and inhi-
bits metastasis in a rat prostate cancer model, inducing
both humoral and cellular responses. We report here
the use of 3M’s hollow microstructured transdermal sys-
tem (hMTS) to determine if this intradermal (ID) deliv-
ery device further enhances immunogenicity of the
NPV.
Methods
Intramuscular (IM) immunization of the NPV was com-
pared with ID administration using the 3M hMTS
device. Male Sprague-Dawley rats (N=6/group) were
immunized with 2.5x1011 phage particles displaying the
N-terminal (HAAH-1l) third of HAAH. Two groups
received one injection either IM via syringe or ID via
hMTS on Day 0, while two additional groups received
IM or ID injections on Days 0, 14 and 28. Repeat injec-
tions using the hMTS device were made to the same
skin site on the dorsal thoracic region.
Results
The vaccine was well tolerated in all groups. No local
injection site or systemic adverse effects were observed
in any animal. Blood samples were obtained on Days 0,
14, 28 and 35 for assessment of antibody levels by
ELISA on recombinant HAAH- or H460 human lung
cancer cell-coated plates. The Day 14 antibody titers
were similar in all groups, while in the two groups that
received three doses of vaccine, the antibody titers were
boosted after each additional injection. Importantly, the
Day 35 antibody titers were much higher using the ID
versus IM immunization when tested on both antigens
(rHAAH coating: 5,777 ID vs. 1,392 IM, p
Conclusion
These data provide evidence that ID delivery of NPV
targeting HAAH using the hMTS device is more effec-
tive than traditional IM delivery in inducing an immune
response. We are preparing an IND to conduct clinical
studies.
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